France · Delayed Price · Currency is EUR Biosynex Statistics
Total Valuation
Biosynex has a market cap or net worth of EUR 16.33 million. The enterprise value is 69.52 million.
| Market Cap | 16.33M |
| Enterprise Value | 69.52M |
Important Dates
The last earnings date was Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biosynex has 18.43 million shares outstanding. The number of shares has increased by 71.42% in one year.
| Current Share Class | 18.43M |
| Shares Outstanding | 18.43M |
| Shares Change (YoY) | +71.42% |
| Shares Change (QoQ) | -3.48% |
| Owned by Insiders (%) | 5.80% |
| Owned by Institutions (%) | n/a |
| Float | 7.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| PB Ratio | 0.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64, with a Debt / Equity ratio of 1.67.
| Current Ratio | 0.64 |
| Quick Ratio | 0.33 |
| Debt / Equity | 1.67 |
| Debt / EBITDA | n/a |
| Debt / FCF | -7.19 |
| Interest Coverage | -5.87 |
Financial Efficiency
Return on equity (ROE) is -95.94% and return on invested capital (ROIC) is -28.92%.
| Return on Equity (ROE) | -95.94% |
| Return on Assets (ROA) | -9.84% |
| Return on Invested Capital (ROIC) | -28.92% |
| Return on Capital Employed (ROCE) | -53.35% |
| Weighted Average Cost of Capital (WACC) | 6.34% |
| Revenue Per Employee | 239,783 |
| Profits Per Employee | -146,660 |
| Employee Count | 397 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.54 |
Taxes
| Income Tax | -1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.84% in the last 52 weeks. The beta is 0.83, so Biosynex's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -28.84% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 0.82 |
| Relative Strength Index (RSI) | 43.09 |
| Average Volume (20 Days) | 24,593 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biosynex had revenue of EUR 95.19 million and -58.22 million in losses. Loss per share was -3.16.
| Revenue | 95.19M |
| Gross Profit | 52.36M |
| Operating Income | -26.05M |
| Pretax Income | -59.24M |
| Net Income | -58.22M |
| EBITDA | -13.64M |
| EBIT | -26.05M |
| Loss Per Share | -3.16 |
Balance Sheet
The company has 8.46 million in cash and 61.65 million in debt, with a net cash position of -53.19 million or -2.89 per share.
| Cash & Cash Equivalents | 8.46M |
| Total Debt | 61.65M |
| Net Cash | -53.19M |
| Net Cash Per Share | -2.89 |
| Equity (Book Value) | 36.89M |
| Book Value Per Share | 2.00 |
| Working Capital | -31.86M |
Cash Flow
In the last 12 months, operating cash flow was -5.89 million and capital expenditures -2.69 million, giving a free cash flow of -8.57 million.
| Operating Cash Flow | -5.89M |
| Capital Expenditures | -2.69M |
| Depreciation & Amortization | 12.41M |
| Net Borrowing | -982,000 |
| Free Cash Flow | -8.57M |
| FCF Per Share | -0.47 |
Margins
Gross margin is 55.00%, with operating and profit margins of -27.36% and -61.16%.
| Gross Margin | 55.00% |
| Operating Margin | -27.36% |
| Pretax Margin | -62.23% |
| Profit Margin | -61.16% |
| EBITDA Margin | -14.33% |
| EBIT Margin | -27.36% |
| FCF Margin | n/a |
Dividends & Yields
Biosynex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -71.42% |
| Shareholder Yield | -71.42% |
| Earnings Yield | -356.53% |
| FCF Yield | -52.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biosynex has an Altman Z-Score of -0.69 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.69 |
| Piotroski F-Score | 2 |